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The relevance of a postantibiotic effect in the treatment of pneumococcal meningitis
was evaluated in a rabbit model. After administration of a single intravenous bolus of
ampicillin at various dosages, such an effect was observed in all animals. The duration
of this effect in vivo (2.5-18 hr) was consistently longer than that in vitro (1-4.3 hr);
however, in rabbits the postantibiotic effect was eliminated by the administration of
intravenous plus intracisternal fJ-Iactamase. In an assessment of the potential therapeu-
tic benefit of the postantibiotic effect, the efficacy of two regimens of treatment with
different intervals between doses was compared. One group of animals received ampicil-
lin every 4 hr and another every 12 hr. With sufficiently high doses, drug concentrations
in cerebrospinal fluid exceeded the minimal bactericidal concentration for most of the
4-hr interval but for only about one-third of the 12-hr interval. The rate of cure was sim-
ilar for the two regimens and approximated 100010 when peak drug concentrations in
cerebrospinal fluid exceeded the minimal bactericidal concentration by at least IO-fold.
The factors that influence efficacy of the treatment
of infectious diseases with antibiotics are not well
defined [1]. Complex interactions between host de-
fense mechanisms, bacteria, and antibiotics and
difficulties associated with the accurate measure-
ment of drug concentrations at the site of infection
make it almost impossible to determine the exact
relation between treatment and effect. Hence, the
relative importance of such pharmacokinetic vari-
ables as peak drug concentration, total dose, pe-
riod during which drug concentrations exceed the
MIC, and interval between doses has not been
studied extensively with regard to most infections.
Bacterial meningitis has several distinguishing
features that make its treatment particularly com-
plex. The blood-CSF barrier limits the penetration
of antibiotics into the CSF [2]; active transport
systems rapidly clear most fJ-lactam drugs from the
CNS [3, 4]; and impaired host-defense mecha-
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nisms in the CSF make bactericidal activity impor-
tant [5, 6]. Since bacterial meningitis is such a dev-
astating disease, the regimens currently recom-
mended consist of large doses of antibiotics given
either at frequent intervals or by constant infusion.
However, with respect to the persistently high mor-
bidity and mortality associated with the disease [7,
8] and the potential toxicity of the antibiotics used
to treat it, a more detailed understanding of the
principles operative in therapy for meningitis
seems important.
We have shown [9] that two intermittent doses of
penicillin (with an interval of 4 hr) are as effective
as a constant infusion of the same amount of drug
over 8 hr in reducing bacterial counts in rabbits
with pneumococcal meningitis. The fact that
trough drug levels below the MBC for the infecting
organisms in 64% of CSF samples did not cause
any apparent loss of bactericidal activity (com-
pared with the activity of the drug at levels that
were constantly above the MBC) suggested that a
postantibiotic effect (PAE) exists in CSF in vivo.
The occurrence of a PAE, defined as delayed re-
growth of bacteria after limited exposure to anti-
biotics, was recognized early in the antibiotic era
[10-12]. Eagle and colleagues documented this
phenomenon in vivo and evaluated its potential
role in the treatment of bacterial infections [13].
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However, the relevance of the PAE for the treat-
ment of meningitis has not been established.
We designed the present study to characterize
the PAE in an animal model of pneumococcal
meningitis and to determine its potential implica-
tions for therapy. We examined the relation be-
tween drug concentration in the CSF and bacterial
growth kinetics at this site over time after a single
iv injection of ampicillin. To evaluate the possibil-
ity that the observed PAE was due to undetectable
drug in the CSF, we characterized the bacterial
growth curves in animals receiving a f3-lactamase
during the PAE. In order to determine the possible
impact of the PAE on therapy, we examined the
relative influence of several pharmacokinetic
variables (dose, peak CSF concentration, interval
between doses) on the outcome of treatment.
Materials and Methods
Organism. A strain of Streptococcus pneumo-
niae type 3 originally isolated from a human adult
with meningitis and characterized earlier [14] was
used in all experiments. The strain was grown in
trypticase soy broth (TSB; Difco Laboratories, De-
troit) supplemented with 50070 inactivated calf se-
rum in a moist atmosphere of 5% CO2-95OJo air at
37 C for 18 hr. The culture was then centrifuged
for 10 min at 7,000 g, resuspended in 0.9070 NaCI,
and stored in l-ml portions containing "-'107 cfu in
the vapor phase of a liquid-nitrogen vessel.
Viable counts. Viable bacterial counts were de-
termined in trypticase soy agar (TSA; Difco) sup-
plemented with either 5% fresh sheep blood or 5%
human blood. Plates were examined after incuba-
tion at 37 C in a moist atmosphere of 5070 CO 2-
95070 air for 18-24 hr. The limit of detectability was
10cfu/ml for 0.1 ml of the culture in broth (in vitro
tests) or CSF.
Antibiotics. A stock solution of 10 mg of am-
picillin/ml (Penbritin's; Beecham, Bristol, Tenn) in
0.9070 NaCI was prepared daily and further diluted
in 0.9% NaCI if required.
Inactivation of ampicillin. Penicillin-amido-f3-
lactamhydrolase (E.C. 3.5.2.6.; Whatman Bio-
chemicals, Maidenhead, Berkshire, England) was
used for hydrolysis of ampicillin in the in vitro ex-
periments. The final concentration of f3-lactamase
was 0.8 unit/ml of agar or 1.6 units/ml of culture
broth [15, 16]. In rabbits, ampicillin was inacti-
vated by iv and intracisternal injection of penicil-
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lin-amido-f3-lactamhydrolase (Riker Laboratories,
Northridge, Calif); each animal simultaneously re-
ceived 300,000 IV by the iv route and 100,000 IV
intracisternally. The activity of f3-lactamase in CSF
was confirmed by the demonstration that the CSF
of control animals given f3-lactamase, as already
described, completely inactivated ampicillin in
vitro.
Antibiotic assay. Concentrations of ampicillin
were determined by an agar well-diffusion tech-
nique [17], with Micrococcus luteus ATCC 9341
(Sarcina lutea) as the test organism. Plates (diam-
eter, 85 mm) were filled with 15 ml of antibiotic
medium no. 1 (Oxoid, London) containing 107 vi-
able cells/ml of agar. Wells (diameter, 8 mm) were
cut and filled with 0.05 ml of CSF sample or
standard dilutions, and zones of inhibition were.
measured after incubation overnight at 37 C. CSF
standards were prepared in 0.9% NaCI, which has
been shown to produce zones identical to those in
infected or uninfected CSF [9].
In vitro studies. The MICs and MBCs of ampi-
cillin were determined by a microtiter method in
heart infusion broth with bacterial inocula of 104
and 106 cfu [14, 18]. The MIC was defined as the
lowest drug concentration that inhibited visible
bacterial growth and the MBC as the lowest con-
centration that killed 99.9% of the organisms over
24 hr. MICs and MBCs were also determined in
pooled rabbit CSF and in broth with a pH of 6.8.
The effects of in vitro exposure of the organisms
to ampicillin were examined by a time-kill re-
growth method [19]. All experiments were per-
formed in TSB plus 50% calf serum by shaking at
200 cycles/min (Mini-Shakers; A. Kuhner, Basel,
Switzerland). A stock culture of S pneumoniae
type 3 was grown for 4 hr in order to obtain orga-
nisms in the logarithmic phase of growth. Portions
(10 ml) of this culture were transferred into 25-ml
flasks containing either ampicillin solutions in
0.9% NaCI or pure 0.9070 NaCI (control flasks).
The time of the transfer was defined as time zero.
Ampicillin was removed at intervals by centrifuga-
tion three times for 10 min at 1,500 g [20] or by
inactivation with .f3-lactamase. Fresh, prewarmed
TSB supplemented with 50% serum was used for
resuspension of bacteria after centrifugation. Vi-
able cell counts were performed on the original in-
oculum before exposure, at the end of the period
of exposure to the drug, and thereafter at required
intervals during the regrowth phase. The PAE was
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calculated as the time necessary for the cultured in-
oculum to increase by 1 10glO cfu/ml after removal
of the antibiotic minus the time required by a con-
trol, unexposed culture to increase by 1 log., cfu/
ml. The same experiment was performed with
pooled CSF (instead of supplemented TSB) and f3-
lactamase for inactivation of ampicillin.
Rabbit model of meningitis. New Zealand
white and Chinchilla rabbits weighing 2-3 kg were
used for the induction of pneumococcal meningi-
tis, as described previously [21]. The rabbits were
anesthetized with pentobarbital (30 mg/kg), and a
dental acrylic helmet was attached to their skulls
by four screws. At least 24 hr later, the animals
were again anesthetized and attached by the helmet
to a stereotactic frame. A Quincke spinal needle (25
gauge, 3 Y2 inches (Becton, Dickinson, Rutherford,
NJ) was introduced atraumatically into the cis-
terna magna with a geared electrode inducer, and
the animals were infected with an inoculum of rv2
x 105 cfu of S pneumoniae in 0.2 m!. The needle
was removed, and the animals were returned to
their cages. Eighteen hours later all animals
demonstrated signs of meningitis (temperature of
~39.6 C, lethargy, CSF pleocytosis, and positive
CSF culture results) [6, 9, 21].
PAE in vivo. At 18 hr the animals were anes-
thetized with 1.5 g of iv-administered urethane/
kg (Merck Sharp and Dohme, Rahway, NJ). The
spinal needle was again introduced into the cister-
na magna, and CSF was withdrawn serially every
2-3 hr for 24 hr for determination of bacterial ti-
ters and drug concentration in CSF. At time zero
the animals received an iv injection of ampicillin at
one of the following doses (in mg/kg): 2, 3, 4, 6,
12.5, 20, or 62.5. In six animals the ampicillin was
inactivated by the iv injection of fJ-lactamase
(300,000 IV by the iv route and 100,000 IV by the
intracisternal route) 2 or 4.5 hr after drug adminis-
tration.
Treatment with different regimens. Animals
were prepared as already described, and CSF for
cultures was obtained by spinal taps performed 18
hr after infection. Animals were then assigned to
one of 10 treatment groups or to a control group
that received no treatment. Treatment consisted of
either two iv injections of ampicillin 12 hr apart or
four iv injections every 4 hr; thus, both regimens
were completed after 12 hr. The dose in each injec-
tion was one of the following (in mg/kg): 4.17,
6.25, 12.5, 25, or 37.5. Peak levels of drug in CSF
577
were determined 30 min after the first injection.
Animals were observed every 4 hr during the exper-
iment (with temperatures determined) and under-
went final evaluation (including sampling of CSF
for culture) 36 hr after the last dose. After each
spinal tap the needle was removed.
Results
Susceptibility. The MIC and MBC of ampi-
cillin for the test strain were 0.06-0.08 JAg/ml with
an inoculum of 104 cfu/ml and 0.1-0.125 ug/ml
with an inoculum of 106 cfu/ml, MICs and MBCs
were identical in broth at pH 7.4, in broth at pH
6.8, and in CSF ex vivo.
Characteristics of the PAE in vitro. Figure 1
shows the principal characteristics of growth of
S pneumoniae in the presence and absence of
ampicillin. In the absence of antibiotics, the bac-
teria grew promptly (in 4 hr) from an initial count
of 6.2 loglo cfu/ml to 8 log., cfu/rnl. The presence
of ampicillin at concentrations at or above the
MBC led to a uniform decline in bacterial titers of
1.5 10glO cfu/ml during the first 2 hr. The rate of
killing was constant over a wide range of ampicil-
lin concentrations (1-100 times the MBC). Re-
moval of the antibiotic after exposure of the or-
ganisms for 2 hr resulted in delayed regrowth (i.e., a
PAE) in all experiments. Whether ampicillin was
inactivated by fJ-lactamase or removed by centri-
fugation and washing, the duration of the PAE in
vitro was the same. Higher drug levels resulted in
a longer PAE (figure 1). The lowest drug concen-
tration that resulted in a measurable PAE was 0.03
JAg of ampicillin/ml (one-half the MIC), with a
PAE duration of 1 hr. At a concentration of 10 JAg
of ampicillin/ml, the PAE lasted for 4.3 hr. When
the same experiments were performed in pooled
rabbit CSF, the level of initial killing during the 2-
hr period of ampicillin exposure was markedly re-
duced (i.e., to 0.5 log., cfu/ml), and the average
generation (or doubling) time of bacterial growth
was increased (from 21 min in broth to 37 min in
CSF). The duration of the PAE, however, was the
same in broth and CSF.
Characteristics of the PAE in vivo. The dy-
namic relation between drug concentrations and
bacterial titers in CSF was examined in 17 animals
that had been infected intracisternally 18-20 hr
prior to the iv administration of ampicillin. The
administration of different drug doses (1-62.5
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Figure 1. Effect of exposure for 2 hr to different concentrations of ampicillin on growth curves of S pneumoniae
in broth. Bacterial titers are plotted as log., cfu/ml against time (hr). The control culture contained no ampicillin.
After exposure for 2 hr to the indicated concentrations of ampicillin, the drug was removed from the culture by centrifu-
gation and three washes.
mg/kg) resulted in a wide range of CSF concentra-
tions (0.04-6.4 ug/rnl); the dose administered and
the resulting peak CSF concentrations correlated.
well (r = .921; P < .001). The dose and the peak
CSF concentrations also correlated (r = .616; P
< .02) with the period during which CSF concen-
trations were above the MIC (median, 4 hr; range,
1-7.5 hr).
The mean bacterial titer (± SD) in CSF was 6.0
(± 1.0) 10glO cfu/ml at the time of drug adminis-
tration. The injection of ampicillin was followed
by a median drop in bacterial titers of 4.4 log.,
cfu/ml (range, 1.9-6.5 10glO cfu/ml). This decline
in bacterial titers correlated with the dose of ampi-
cillin administered (r = .619; P < .01).
The total drug effect, defined as the period from
the injection of ampicillin to the beginning of bac-
terial regrowth (figure 2), lasted for a median of 11
hr (range, 3.5-20 hr) and correlated with the ampi-
cillin dose (rs = .488; P < .05). In animals receiv-
ing doses of ampicillin that produced peak CSF
concentrations of ~10 times the MBC, the total
duration of the drug's effect consistently exceeded
12 hr. The PAE, defined as the total duration of
the drug's effect minus the period during which
drug concentrations were above the MIC (figure
2), ranged from 2.5 hr to 18 hr (median, 6.5 hr) and
did not correlate with either the dose of ampicillin
or the peak concentration of ampicillin in CSF (r
= .050; P = not significant).
Effect of [3-lactamase on the PAE in vivo. In
six additional animals that were prepared identi-
cally, the administration of an iv bolus of 12.5 mg
of ampicillin/kg was followed by the injection of
400,000 IV of [3-lactamase (300,000 IV by the iv
route and 100,000 IV into the cisterna magna)
after 2 hr or 4.5 hr. In all animals the injection of
[3-lactamase reversed the PAE. In both treatment
groups, bacterial titers in CSF had increased by an
average of 0.5 log., cfu/ml 0.5 hr after administra-
tion of the enzyme and by 0.9 10glO cfu/ml 1 hr
after the injection (figure 3).
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Figure 2. Relation of ampicillin con-
centrations and bacterial titers in CSF
of a representative rabbit that received
12.5 mg of ampicillin/kg iv at time
zero. Drug concentrations and bac-
terial titers were determined in serial
samples of CSF.
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Figure 3. Effect of inactivation of ampicillin in CSF
by injection of fJ-Iactamase (t) in two representative rab-
bits. Each animal received 12.5 mg of ampicillin/kg iv
18 hr after being infected. Bacterial titers of S pneumoniae
were determined in CSF over time. The animals received
400,000 IV of fJ-Iactamase (300,000 IV by the iv route
and 100,000 IV intracisternally) 2 hr and 4.5 hr after the
injection of ampicillin.
large doses, with peak CSF concentrations of >10
times the MBC, sterilized the CSF of >90010 of the
animals, regardless of other variables in the treat-
ment regimen (table 1). When regimens consisting
of the same single dose but different total doses
and intervals between doses (four doses at 4-hr in-
tervals vs. two doses at 12-hr intervals) were com-
pared, the more frequent dosing regimen appeared
to be preferable but differences did not reach sta-
tistical significance (P ~ .2). On the other hand,
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Influence of different regimens on therapeutic
efficacy. A total of 235 rabbits with meningitis
were used in studies of the influence of different
doses of ampicillin and different intervals between
doses on sterilization of CSF cultures 36 hr after
the last injection. The 28 untreated control rabbits
all died within 66 hr of bacterial inoculation or
had positive CSF culture results (mean, 105 cfu/ml)
and fever (~39.6 C); no spontaneous cures were
observed. The remaining 207 animals were as-
signed to the various treatment groups. Therapy
was initiated 18 hr after infection, when 100% of
the animals had fever and positive CSF culture re-
sults (3.9 ± 1.2 log., cfu/ml). Forty-nine rabbits
had to be excluded from the evaluation either
because they died before the completion of the 66-
hr experiment (n = 15) or because no CSF could
be obtained for the final evaluation (n = 34). The
majority of the early deaths resulted from experi-
mental procedures. Since evaluation of the results
depended on the result of culture of the final CSF
sample, data on all animals that could not be clas-
sified with certainty for one of the reasons men-
tioned were excluded. Even if all deaths had been
counted as treatment failures, the outcome would
not have been significantly changed.
The two most important factors determining
outcome in our experiments were the dose in a
single injection of ampicillin and the peak drug
concentrations in CSF. As previously stated, these
two variables are closely related. Small single
doses, which produced peak CSF concentrations
of 0.2-0.5 ug/ml (two to five times the MBC), in-
consistently resulted in sterile CSF; in contrast,
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Table 1. Results of ampicillin treatment of meningitis caused by S pneumoniae in rabbits.
------
Single
dose (mg/kg)
o
4.17
4.17
6.25
6.25
12.5
12.5
25.0
25.0
37.5
37.5
No. of
doses
o
2
4
2
4
2
4
2
4
2
4
Total
dose (mg/kg)
o
8.34
16.68
12.5
25
25
50
50
100
75
150
Mean peak drug
level in CSF (± SO)
o
0.20 ± 0.09
0.20 ± 0.14
0.20 ± 0.08
0.28 ± 0.16
0.52 ± 0.37
0.54 ± 0.35
1.14 ± 0.54
1.44 ± 0.46
1.44 ± 1.26
1.55 ± 0.89
No. of animals with sterile CSF /
no. evaluated (010 with sterile CSF)*
0/28 ( )
0/10 ( )
1/9 (11)
4/19 (21)
9/21 (43)
13/23 (57)
19/24 (79)
21/22 (95)
8/8 (100)
11/12 (92)
10/10 (100)
* Each pair of results listed consecutively in the table was compared by the X2 test or the Fisher's exact test. In all cases the differ-
ences between values were insignificant (P > .05).
when regimens with the same total dose were com-
pared, those involving drug administration every
12 hr (which resulted in higher individual peak
CSF concentrations) were found to be slightly ad-
vantageous but not significantly so (P ~ .2).
Another variable that may influence the bacteri-
ologic response is the proportion of the interval be-
tween doses during which CSF concentrations
exceed the MIC. Our preliminary experiments
showed that CSF concentrations are above the
MIC for ""4 hr after an injection of 12.5mg of am-
picillin/kg and for ""6 hr after a dose of 37.5
mg/kg. Thus, regimens with single doses of 12.5
mg/kg administered every 4 hr result in CSF con-
centrations above the MIC for 100070 of the in-
terval between doses (i.e., the whole period of
treatment), while those with single doses of 37.5
mg/kg administered every 12 hr produce CSF con-
centrations that exceed the MIC for (at most) 50070
of the time. Our results did not show a significant
influence of the interval between doses on the
results of treatment. However, when the single
dose administered every 12 hr was increased from
12.5 mg/kg to 25 mg/kg, the outcome of treatment
was significantly better (P < .01), even though the
period during which CSF concentrations were
above the MIC increased only from 30% to 40%
of the interval between doses. Thus, our results
indicate that the period during which CSF concen-
trations exceed the MIC is not a major determi-
nant of outcome within the limits examined (i.e.,
with CSF concentrations above the MIC for >30070
of the interval between doses).
Thus, the size of the single dose of ampicillin
and the peak concentration of the drug in CSF de-
termine the bacteriologic result in our animal
model of meningitis. Doses that result in peak CSF
concentrations of >10 times the MBC are highly
effective, with sterile CSF in >90070 of cases. The
total amount of drug given during the period of
treatment, the interval between doses, and the
period during which the drug concentration in the
CSF is above the MIC appear to be of minor
importance.
Discussion
Early in the antibiotic era, Parker and colleagues
[10, 11] observed that the inhibitory effect of peni-
cillin on staphylococci in vitro persisted for some
time after removal of the drug. This PAE has since
been reproduced in vitro with many different or-
ganisms and antibiotics [12, 19, 22]. A few years
after Parker's initial observations, Eagle and col-
leagues conducted a series of experiments on the
importance of several variables of antibiotic treat-
ment, including the PAE, in mice and rabbits [13,
23, 24]. These investigators found that a PAE simi-
lar to that found in vitro also existed in vivo, that
an increase of doses above a critical value did not
enhance the bactericidal action of penicillin, and
that the most important variable determining out-
come was the period during which the concentra-
tion of drug was maintained above the MIC. Inter-
est in these questions has persisted. Most recently,
studies conducted with a thigh model of pneumo-
coccal infection in neutropenic mice demonstrated
that penicillin produced a PAE only after the ad-
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ministration of large doses and prolonged expo-
sure, whereas erythromycin and tetracycline pro-
duced a PAE similar to that observed in vitro [25].
Furthermore, the period during which drug con-
centrations were above the MIC was found to be
the most important factor determining the results
of treatment in these experiments [25, 26]; these
observations were similar to those of Eagle et al.
[23,24]. In another study Bakker-Woudenberg and
associates examined the effectiveness of penicillin
against pneumococcal pneumonia in decomple-
mented rats and confirmed the importance of pro-
longed periods during which drug concentrations
exceeded the MIC for maximal therapeutic bene-
fit [27].
The understanding of pharmacokinetic factors
that influence the efficacy of therapy for bacterial
meningitis is incomplete. Preliminary studies in a
rabbit model of pneumococcal meningitis have
suggested that a PAE exists in CSF [9], but the role
of this PAE and its relation to other variables, such
as dose and duration of drug exposure, have not
been investigated.
The PAE documented in our studies in vivo of
CSF differed in several respects from the PAE ob-
served in vitro. The former lasted considerably
longer than the latter (2.5-18 hr vs. 1-4.3 hr) and
was considerably more variable. The duration of
the in vivo PAE did not correlate with the dose or
the peak concentration of ampicillin in CSF and
could be reversed by the administration of fJ-Iacta-
rnase, which inactivated residual drug in the sub-
arachnoid space.
These characteristics suggest that the PAE ob-
served in our animal model of meningitis may be
a different phenomenon from the PAE observed in
vitro. The strongest evidence for this hypothesis
derives from the striking effect of fJ-Iactamase
administration on the PAE in vivo. Our findings
indicate that the in vivo effect is the consequence
of the presence of small residual amounts of drug
in CSF. When this drug is inactivated, no further
PAE can be documented. This result is in contrast
to that in vitro, where the PAE was found (in both
this study and that of McDonald et al. [19]) to be
unaffected by fJ-Iactamase.
If the PAE in CSF is indeed attributable to the
presence of small residual amounts of drug, its
duration should reflect the pharmacokinetic char-
acteristics of drug elimination from CSF. In earlier
studies we found considerable variation of CSF
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pharmacokinetics in infected rabbits [14, 28], and
the slow gamma phase of drug elimination is prob-
ably subject to similar variability. Furthermore, the
duration of the gamma phase is probably a func-
tion not only of the initial CSF concentrations but
also of other factors that can influence CSF
pharmacokinetics (e.g., degree of inflammation,
rate of CSF turnover). Thus, the observed variabil-
ity of the PAE and its lack of correlation with the
initial CSF peak in vivo may simply be the expres-
sions of pharmacokinetic differences that affect
the duration of the gamma phase of drug elimina-
tion in individual rabbits.
In the absence of active drug in CSF (i.e., after
fJ-Iactamase administration), we did not find a
PAE in our model. This result is in agreement with
the findings of other researchers who, examining
the occurrence of a PAE in neutropenic mice in-
fected with S pneumoniae, found either no PAE
[26] or only a short PAE after prolonged exposure
to large doses of penicillin [25]. Conversely, Eagle
et al. documented a sustained PAE in a mouse
model in the apparent absence of any residual drug
[13]. The reasons for these discrepancies are not
clear. Eagle and Musselman showed that only
actively growing organisms exhibited a PAE in
vitro [12]. Pneumococci in CSF in vivo grow con-
siderably more slowly than in broth, with genera-
tion times of 60 min and 20 min, respectively [29].
It is questionable, though, whether this difference
in growth rate is the main reason for the absence
of a drug-independent PAE in vivo since our in
vitro studies showed no influence of the prolonged
generation time in ex vivo CSF on the duration of
the PAE.
Another interesting fact is that a PAE was ob-
served in immunocompetent animals by Eagle
et al. [13], whereas no drug-independent PAE
could be documented in immunodeficient animals
(neutropenic mice) [26] or in animals infected at a
site of impaired host defenses (meningitis). It is
conceivable that the occurrence of a PAE in vivo
withS pneumoniae after exposure to penicillin is
dependent on either the presence of residual
amounts of drug 'or functioning host-defense
mechanisms.
The relevance of a PAE to therapy is difficult to
assess unequivocally. The pharmacologic param-
eter best suited to reflect the influence of the PAE
is the interval between doses. However, when this
interval is varied so that its influence on outcome
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can be assessed, at least one other variable (the
number of doses, the dose administered in a single
injection, the total dose, or the duration of treat-
ment) must also be changed. In our study we com-
pared two different intervals (4 hr and 12 hr),
varying the single and total doses of ampicillin
while keeping the total duration of therapy con-
stant (12 hr).
The most important factor determining efficacy
of treatment in our experiments was the peak con-
centration of ampicillin in CSF. The outcome of
treatment improved as drug concentrations in CSF
increased, and peak concentrations that were >10
times the MBC consistently resulted in sterile CSF
in >90% of animals. On the other hand, within the
limits of the dosing schedules examined, the inter-
val between doses and the duration of CSF ampi-
cillin concentrations above the MIC did not ap-
pear to be of major importance with regard to
outcome. If anything, prolonging of the interval
between doses (with a constant amount of total
drug) resulted in a favorable trend throughout all
treatment groups; this effect was probably due to
the resulting higher peak concentrations in CSF.
Thus, even with small doses of drug, the benefit of
the enhanced killing rate by the higher peak con-
centrations of ampicillin in CSF [30] seems to out-
weigh the hazard of eventual bacterial regrowth
toward the end of the dosing interval. With large
doses the total antibiotic effect observed in our
preliminary experiments is apparently of sufficient
duration to prevent bacterial regrowth during the
12-hr interval between doses.
Our findings are in contrast to those of Eagle et
al. [13, 23, 24] and Gudmundsson et al. [26], which
suggested that the duration of drug concentrations
above the MIC was the most important determi-
nant of outcome and that peak drug concentra-
tions wereof only minor import. It is possible that
the unique characteristics of meningitis (i.e., bac-
terial growth conditions in CSF, pharmacokinetics
in CSF, impaired host defenses in the subarach-
noid space) are responsible for these discrepancies.
Since the observed PAE in meningitis appears to
be the result of a prolonged gamma phase of am-
picillin elimination, direct extrapolation to infec-
tions at sites with different pharmacokinetics is
not possible. Also, since the PAE may vary con-
siderably from one antibiotic to another and from
one organism to another [22], our results apply
only to the drug and organism tested.
Tauber et al.
Our findings emphasize points of potential im-
portance in the treatment of pneumococcal menin-
gitis. If it is to effect maximal bacterial killing, the
dose of drug administered must result in peak CSF
concentrations far above the MBC for the patho-
gen. This notion has been confirmed in a recent
study of the relation between the concentrations of
severalf3-lactam antibiotics in CSF and the bacteri-
cidal effect of these drugs [30] and has also been
supported by clinical experiences [5, 31, 32]. In
addition, the drug-dependent PAE in CSF prevents
immediate bacterial regrowth after drug concen-
trations drop below the MIC. The complexity of
our model dictated the inclusion of only relatively
small numbers of animals in each treatment group.
The large inherent f3-error that results from these
small numbers precludes a definite statement
about equality of the two intervals between doses.
Nevertheless, our study demonstrates that the pro-
longed prevention of bacterial regrowth observed
in vivo in CSF is associated with therapeutic effi-
cacy. Furthermore, contrary to findings by Schmidt
and Walley in experiments with a rat model of
pneumococcal pneumonia [33], our studies failed
to demonstrate a clear-cut advantage of long inter-
vals between doses of drug. Thus, while our data
suggest that an increase in these intervals can result
in rates of cure similar to those obtained with sus-
tained, high concentrations of drug in CSF as long
as the peak concentration reaches a critical value
(~10 times the MBC), they do not support the con-
cept that a prolonged therapeutic interval is
superior.
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